Eliem Therapeutics holder plans Rule 144 share sale

Eliem Therapeutics (symbol EWTX) has a holder planning to sell common shares under Rule 144.

Rhea-AI Filing Summary

Eliem Therapeutics (symbol EWTX) has a holder planning to sell common shares under Rule 144. The notice covers 115,471 shares of common stock to be sold through J.P. Morgan Securities LLC on the Nasdaq market, with an approximate sale date of 01/21/2026. The aggregate market value of the planned sale is listed as 3,353,279, compared with 105,868,434 common shares outstanding.

The shares to be sold were acquired on 01/21/2026 through a stock option exercise from the issuer, paid for in cash on the same date. The person signing the notice represents that they are not aware of any material adverse, nonpublic information about the issuer’s current or future operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for EWTX disclose?

The filing discloses that a holder of Eliem Therapeutics (EWTX) common stock plans to sell 115,471 shares under Rule 144 on Nasdaq through J.P. Morgan Securities LLC.

How many Eliem Therapeutics (EWTX) shares are covered by this planned sale?

The notice covers 115,471 shares of EWTX common stock to be sold under Rule 144.

What is the aggregate market value of the EWTX shares to be sold?

The aggregate market value of the planned sale is listed as 3,353,279 for the 115,471 common shares to be sold.

How does the planned EWTX sale compare to total shares outstanding?

The notice states that 105,868,434 EWTX common shares are outstanding, providing context for the 115,471 shares covered by this Form 144.

How were the Eliem Therapeutics (EWTX) shares being sold acquired?

The 115,471 EWTX common shares were acquired on 01/21/2026 through a stock option exercise from the issuer, with cash payment on the same date.

When is the planned sale date for the EWTX shares under this Form 144?

The filing lists an approximate sale date of 01/21/2026 for the 115,471 EWTX common shares to be sold on Nasdaq.

Does the Form 144 filer make any representation about nonpublic information on EWTX?

Yes. By signing, the person for whose account the EWTX securities are to be sold represents that they do not know any material adverse information about the issuer’s operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 04:05 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001786966
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Edgewise Therapeutics, Inc.
SEC File Number	001-40236
Address of Issuer	1715 38th Street Boulder Boulder COLORADO 80301
Phone	720-262-7002
Name of Person for Whose Account the Securities are To Be Sold	Badreddin Edris
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	J.P. Morgan Securities LLC 270 Park Avenue 10th floor New York NY 10017	115471	3353279	105868434	01/21/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/21/2026	Stock Option Exercise	Issuer			115471	01/21/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	01/21/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/24/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Badreddin Edris.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)